Keywords: cytogen, mabs, acquired, worldwide, rights, unipath, cancer-based

CYTOGEN MAbs

Article | 15 February 1993

Cytogen has acquired worldwide rights to Unipath's cancer-based monoclonal antibody R&D program. Unipath is the medical products arm of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in